Anthera Pharmaceuticals (Anthera Pharmaceuticals) EV-to-EBIT

Anthera Pharmaceuticals Annual Data
	Trend	Dec08	Dec09	Dec10	Dec11	Dec12	Dec13	Dec14	Dec15	Dec16	Dec17
EV-to-EBIT							-1.83	-1.18	-3.93	-0.32	-0.58

Anthera Pharmaceuticals Quarterly Data
	Jun13	Sep13	Dec13	Mar14	Jun14	Sep14	Dec14	Mar15	Jun15	Sep15	Dec15	Mar16	Jun16	Sep16	Dec16	Mar17	Jun17	Sep17	Dec17	Mar18
EV-to-EBIT																-0.25	-0.11	-0.26	-0.57	-0.01

For the Biotechnology subindustry, Anthera Pharmaceuticals's EV-to-EBIT, along with its competitors' market caps and EV-to-EBIT data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

For the Biotechnology industry and Healthcare sector, Anthera Pharmaceuticals's EV-to-EBIT distribution charts can be found below:

* The bar in red indicates where Anthera Pharmaceuticals's EV-to-EBIT falls into.

Anthera Pharmaceuticals EV-to-EBIT Calculation

Anthera Pharmaceuticals's EV-to-EBIT for today is calculated as:

Anthera Pharmaceuticals's current Enterprise Value is $0.00 Mil.
Anthera Pharmaceuticals's EBIT for the trailing twelve months (TTM) ended in Mar. 2018 adds up the quarterly data reported by the company within the most recent 12 months, which was $-36.70 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Anthera Pharmaceuticals  (OTCPK:ANTH) EV-to-EBIT Explanation

This is a more accurate valuation of companies' operation because it considers the debt and cash on its balance sheet, and non-operating items such as interest payment, tax, and one-time items are not included in the Operating Income.

Joel Greenblatt calls the inversion of this ratio Earnings Yield (Joel Greenblatt) %.

Anthera Pharmaceuticals's Earnings Yield (Joel Greenblatt) % for the quarter that ended in Mar. 2018 is calculated as:

Anthera Pharmaceuticals's Enterprise Value for the quarter that ended in Mar. 2018 was $0.29 Mil.
Anthera Pharmaceuticals's EBIT for the trailing twelve months (TTM) ended in Mar. 2018 adds up the quarterly data reported by the company within the most recent 12 months, which was $-36.70 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Anthera Pharmaceuticals EV-to-EBIT Related Terms

Thank you for viewing the detailed overview of Anthera Pharmaceuticals's EV-to-EBIT provided by GuruFocus.com. Please click on the following links to see related term pages.

Anthera Pharmaceuticals (Anthera Pharmaceuticals) Business Description